Search Results - "Bujanda, L"

Refine Results
  1. 1

    Mechanisms of Resistance to Chemotherapy in Gastric Cancer by Marin, J J G, Al-Abdulla, R, Lozano, E, Briz, O, Bujanda, L, Banales, J M, Macias, R I R

    Published in Anti-cancer agents in medicinal chemistry (01-01-2016)
    “…Although surgical resection is the standard curative therapy for gastric cancer, these tumors are often diagnosed at an advanced stage, when surgery is not…”
    Get more information
    Journal Article
  2. 2

    Peptic Ulcer Bleeding Risk. The Role of Helicobacter Pylori Infection in NSAID/Low-Dose Aspirin Users by Sostres, C, Carrera-Lasfuentes, P, Benito, R, Roncales, P, Arruebo, M, Arroyo, M T, Bujanda, L, García-Rodríguez, L A, Lanas, A

    Published in The American journal of gastroenterology (01-05-2015)
    “…Helicobacter pylori (H. pylori) infection and NSAID/low-dose aspirin (ASA) use are associated with peptic ulcer disease. The risk of peptic ulcer bleeding…”
    Get full text
    Journal Article
  3. 3

    Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress by Gómez-Zorita, S., Fernández-Quintela, A., Macarulla, M. T., Aguirre, L., Hijona, E., Bujanda, L., Milagro, F., Martínez, J. A., Portillo, M. P.

    Published in British journal of nutrition (28-01-2012)
    “…Non-alcoholic fatty liver disease (NAFLD) is one of the most common manifestations of chronic liver disease worldwide. The aim of the present study was to…”
    Get full text
    Journal Article
  4. 4

    SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells by Herreros-Villanueva, M, Zhang, J-S, Koenig, A, Abel, E V, Smyrk, T C, Bamlet, W R, de Narvajas, A A-M, Gomez, T S, Simeone, D M, Bujanda, L, Billadeau, D D

    Published in Oncogenesis (New York, NY) (05-08-2013)
    “…SOX2 (Sex-determining region Y (SRY)-Box2) has important functions during embryonic development and is involved in cancer stem cell (CSC) maintenance, in which…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7

    MicroRNAs and extracellular vesicles in cholangiopathies by Olaizola, P., Lee-Law, P.Y., Arbelaiz, A., Lapitz, A., Perugorria, M.J., Bujanda, L., Banales, J.M.

    “…Cholangiopathies encompass a heterogeneous group of disorders affecting biliary epithelial cells (i.e. cholangiocytes). Early diagnosis, prognosis and…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10

    Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori by Cosme, A., Montes, M., Martos, M., Gil, I., Mendarte, U., Salicio, Y., Piñeiro, L., Recasens, M.T., Ibarra, B., Sarasqueta, C., Bujanda, L.

    Published in Clinical microbiology and infection (01-04-2013)
    “…The rate of eradication of Helicobacter pylori with standard triple therapy using omeprazole, amoxicillin and clarithromycin (OAC) is unacceptable in…”
    Get full text
    Journal Article
  11. 11
  12. 12
  13. 13

    Diagnostic accuracy of the faecal immunochemical test for colorectal cancer in symptomatic patients: comparison with NICE and SIGN referral criteria by Cubiella, J., Salve, M., Díaz-Ondina, M., Vega, P., Alves, M. T., Iglesias, F., Sánchez, E., Macía, P., Blanco, I., Bujanda, L., Fernández-Seara, J.

    Published in Colorectal disease (01-08-2014)
    “…Aim The diagnostic accuracy of the faecal immunochemical test (FIT) at a 100 ng/ml threshold for colorectal cancer (CRC) was compared with National Institute…”
    Get full text
    Journal Article
  14. 14
  15. 15

    The changing face of hospitalisation due to gastrointestinal bleeding and perforation by Lanas, A., García‐Rodríguez, L. A., Polo‐Tomás, M., Ponce, M., Quintero, E., Perez‐Aisa, M. A., Gisbert, J. P., Bujanda, L., Castro, M., Muñoz, M., Del‐Pino, M. D., Garcia, S., Calvet, X.

    Published in Alimentary pharmacology & therapeutics (01-03-2011)
    “…Aliment Pharmacol Ther 2011; 33: 585–591 Summary Background  Temporal changes in the incidence of cause‐specific gastrointestinal (GI) complications may be one…”
    Get full text
    Journal Article
  16. 16
  17. 17

    New Advances in Polycystic Liver Diseases by Santos-Laso, A, Izquierdo-Sánchez, L, Lee-Law, P Y, Perugorria, M J, Marzioni, M, Marin, J J G, Bujanda, L, Banales, J M

    Published in Seminars in liver disease (01-02-2017)
    “…Polycystic liver diseases (PLDs) include a heterogeneous group of congenital disorders inherited as dominant or recessive genetic traits; they are manifested…”
    Get more information
    Journal Article
  18. 18
  19. 19

    Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer by Jover, R, Zapater, P, Castells, A, Llor, X, Andreu, M, Cubiella, J, Piñol, V, Xicola, R M, Bujanda, L, Reñé, J M, Clofent, J, Bessa, X, Morillas, J D, Nicolás-Pérez, D, Payá, A, Alenda, C

    Published in Gut (01-06-2006)
    “…Aim: Some retrospective studies have shown a lack of benefit of 5-fluorouracil (5-FU) adjuvant chemotherapy in patients with mismatch repair (MMR) deficient…”
    Get full text
    Journal Article
  20. 20

    Several statins increase body and liver fat accumulation in a model of metabolic syndrome by Aguirre, L, Hijona, E, Macarulla, M T, Gracia, A, Larrechi, I, Bujanda, L, Hijona, L, Portillo, M P

    “…Statins are a family of drugs used in hypercholesterolemia. The aim of this study was to analyze the effect of statins on body and liver fat accumulation in…”
    Get more information
    Journal Article